

United States Autoinjector Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2789.00
- Five User License \$3909.00
- Corporate License \$5099.00

Report description:

The United States autoinjector market was valued at USD 0.65 Billion in 2024, driven by the regulatory support and technological advancements in the region. The market is anticipated to grow at a CAGR of 14.20% during the forecast period of 2025-2034, with the values likely to reach USD 2.45 Billion by 2034. The market is driven by growing demand for self-administered therapies, advancements in smart autoinjectors, and increased adoption in home healthcare due to rising chronic disease prevalence.

United States Autoinjector Market Overview

Autoinjector devices are prefilled, self-administering drug delivery systems designed for rapid, accurate, and convenient injection without professional assistance. The market for autoinjectors in the United States is experiencing significant growth, driven by rising chronic disease prevalence, increasing self-medication trends, and technological advancements enhancing patient compliance and safety.

United States Autoinjector Market Growth Drivers

Next-Generation Testing Technology Set to Augment Market Demand

Integrating advanced testing systems will enhance the reliability and quality assurance of autoinjector devices. For instance, in June 2024, Instron launched its next-generation autoinjector testing system, enabling comprehensive functionality testing on a single platform. By streamlining validation and production transfer processes, this innovation supports efficiency and product safety, ultimately accelerating market growth.

United States Autoinjector Market Trends

Some of the notable trends in the market include expanding regulatory approvals for injectable therapies and increasing government initiatives focused on emergency preparedness and access to critical self-injection treatments.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Regulatory Advancements is Poised to Accelerate Market Growth

Expanding regulatory approvals for treatments represent a significant trend in the autoinjector devices market. In August 2024, the U.S. FDA approved Zurnai, the first nalmefene hydrochloride auto-injector for emergency opioid overdose treatment. This milestone, in alignment with the FDA's overdose prevention framework, is anticipated to foster innovation and accelerate market growth.

Rising Government Initiatives in Emergency Preparedness is Likely to Elevate United States Autoinjector Market Value

A growing trend in the market is the increased investment in emergency preparedness and public health response. In April 2025, Barda's funding to Kaleo for developing 2-PAM autoinjectors highlighted the government's commitment to enhancing rapid-response capabilities. Such initiatives are expected to drive market growth by advancing autoinjector innovation and expanding strategic stockpiles.

United States Autoinjector Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

- Disposable
- Reusable

- ??- Empty
- ??- Prefilled

Market Breakup by Volume

- Up to 3ml
- Above 3ml

Market Breakup by Technology

- Automatic
- Manual

Market Breakup by Route of Administration

- Subcutaneous
- Intramuscular

Market Breakup by Application

- Autoimmune Disorders
- Rheumatoid Arthritis
- Diabetes

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Multiple Sclerosis
- Anaphylaxis
- Others

Market Breakup by End User

- Hospitals & Clinics
- Homecare Settings
- Ambulatory Surgical Centers
- Others

United States Autoinjector Market Share

Segmentation Based on Application to Witness Substantial Growth

Based on the type, the market is segmented into disposable and reusable. The disposable segment is anticipated to have a substantial share of the market, driven by increasing demand for hygienic and single-use medical products across healthcare settings. Enhanced infection control protocols, cost-effectiveness in bulk procurement, and minimal maintenance requirements contribute to its widespread adoption. Additionally, the growing preference in outpatient and homecare environments further strengthens the segment's projected market dominance.

United States Autoinjector Market Analysis by Region

The autoinjector devices market in the United States demonstrates strong regional performance, with leading growth observed in the Mideast and Southeast regions. These areas benefit from advanced healthcare infrastructure, high chronic disease prevalence, and increasing patient awareness. Additionally, the Southwest regions contribute significantly, driven by rising demand for self-administration solutions and supportive healthcare policies.

Leading Players in the United States Autoinjector Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Eli Lilly and Company

Eli Lilly and Company, founded in 1876 and headquartered in Indianapolis, Indiana, plays a pivotal role in the market. In August 2024, the company expanded access to Zepbound (tirzepatide) by introducing single-dose vials and autoinjector pens for adults with obesity. This launch enhances treatment accessibility and supports patients with self-administered, subcutaneous weight management solutions. Teva Pharmaceuticals: Teva Pharmaceuticals plays a significant role in the autoinjector market. It was established in 1901 and is headquartered in Tel Aviv, Israel. The company offers Epinephrine injection, USP (auto-injector), a generic equivalent to EpiPen and EpiPen Jr. These pre-filled, single-dose autoinjectors are used in the emergency treatment of allergic reactions, highlighting Teva's commitment to accessible, life-saving therapies.

Ypsomed

Ypsomed, headquartered in Burgdorf, Switzerland, was established in 1984 and is actively contributing to the autoinjector devices market. The company's innovative product, YpsoMate On, is a pre-filled autoinjector featuring integrated connectivity that logs

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

injections automatically and enhances therapy adherence. Recognized with the Pharmapack 2022 Innovation Award, it supports digital therapy management with a sustainable, user-friendly design.

SHL Medical

SHL Medical, established in 1989, is headquartered in Switzerland. The company specializes in the development, manufacturing, and assembly of drug delivery devices, including autoinjectors. In 2022, SHL Medical expanded into the U.S. market with a new facility in North Charleston, South Carolina. Their product lineup includes the Molly autoinjectors, designed for self-injection systems, crucial for treating chronic diseases. This move enhances their ability to meet growing demand in the U.S. autoinjector devices market.

Other key players in the market include Pfizer, Inc., Amgen, Sanofi, Mylan N.V., and Biogen.

Key Questions Answered in the United States Autoinjector Market Report

- What was the United States autoinjector market value in 2024?
- What is the United States autoinjector market forecast outlook for 2025-2034?
- What is the market segmentation based on type?
- What is the market segmentation based on volume?
- What is the market segmentation based on technology?
- What is the market breakup based on the route of administration?
- How is the market segmented based on application?
- How is the market divided based on the end user?
- What are the major factors aiding the United States autoinjector market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major United States autoinjector market trends?
- Which type is expected to dominate the market segment?
- Which volume is expected to dominate the market segment?
- Which technology is expected to dominate the market segment?
- Which route of administration is projected to lead the market segment?
- Which application is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players involved in the United States autoinjector market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 United States Autoinjector Market Overview
 - 3.1 North America Autoinjector Market
 - 3.1.1 North America Autoinjector Market Historical Value (2018-2024)
 - 3.1.2 North America Autoinjector Market Forecast Value (2025-2034)
 - 3.2 United States Autoinjector Market
 - 3.2.1 United States Autoinjector Market Historical Value (2018-2024)
 - 3.2.2 United States Autoinjector Market Forecast Value (2025-2034)
- 4 United States Autoinjector Market Landscape*
 - 4.1 United States Autoinjector Market: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 United States Autoinjector Market: Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Volume
 - 4.2.3 Analysis by Technology
 - 4.2.4 Analysis by Route of Administration
 - 4.2.5 Analysis by Application
- 5 United States Autoinjector Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 PESTEL Analysis
 - 5.3.1 Political
 - 5.3.2 Economic
 - 5.3.3 Social
 - 5.3.4 Technological
 - 5.3.5 Legal
 - 5.3.6 Environment
 - 5.4 Porter's Five Forces Model
 - 5.4.1 Bargaining Power of Suppliers
 - 5.4.2 Bargaining Power of Buyers
 - 5.4.3 Threat of New Entrants
 - 5.4.4 Threat of Substitutes
 - 5.4.5 Degree of Rivalry
 - 5.5 Key Demand Indicators
 - 5.6 Key Price Indicators
 - 5.7 Industry Events, Initiatives, and Trends
 - 5.8 Value Chain Analysis
- 6 United States Autoinjector Market Segmentation (218-2034)
 - 6.1 United States Autoinjector Market (2018-2034) by Type
 - 6.1.1 Market Overview
 - 6.1.2 Disposable
 - 6.1.3 Reusable

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.3.1 Empty
- 6.1.3.2 Prefilled
- 6.2 United States Autoinjector Market (2018-2034) by Volume
 - 6.2.1 Market Overview
 - 6.2.2 Up to 3ml
 - 6.2.3 Above 3ml
- 6.3 United States Autoinjector Market (2018-2034) by Technology
 - 6.3.1 Market Overview
 - 6.3.2 Automatic
 - 6.3.3 Manual
- 6.4 United States Autoinjector Market (2018-2034) by Route of Administration
 - 6.4.1 Market Overview
 - 6.4.2 Subcutaneous
 - 6.4.3 Intramuscular
- 6.5 United States Autoinjector Market (2018-2034) by Application
 - 6.5.1 Market Overview
 - 6.5.2 Autoimmune Disorders
 - 6.5.3 Rheumatoid Arthritis
 - 6.5.4 Diabetes
 - 6.5.5 Multiple Sclerosis
 - 6.5.6 Anaphylaxis
 - 6.5.7 Others
- 6.6 United States Autoinjector Market (2018-2034) by End User
 - 6.6.1 Market Overview
 - 6.6.2 Hospitals & Clinics
 - 6.6.3 Homecare Settings
 - 6.6.4 Ambulatory Surgical Centers
 - 6.6.5 Others
- 7 Regulatory Framework
- 8 Patent Analysis
 - 8.1 Analysis By Phase of Patent
 - 8.2 Analysis by Publication Year
 - 8.3 Analysis by Issuing Authority
 - 8.4 Analysis by Patent Age
 - 8.5 Analysis by CPC Analysis
 - 8.6 Analysis by Patent Valuation
- 9 Funding and Investment Analysis
 - 9.1 Analysis by Funding Instances
 - 9.2 Analysis by Type of Funding
 - 9.3 Analysis by Funding Amount
 - 9.4 Analysis by Leading Players
 - 9.5 Analysis by Leading Investors
 - 9.6 Analysis by Geography
- 10 Strategic Initiatives
 - 10.1 Analysis by Partnership Instances
 - 10.2 Analysis by Type of Partnership
 - 10.3 Analysis by Leading Players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4 Analysis by Geography
- 11 Supplier Landscape
 - 11.1 Market Share Analysis (Top 5 Companies)
 - 11.2 Eli Lilly and Company
 - 11.2.1 Financial Analysis
 - 11.2.2 Product Portfolio
 - 11.2.3 Demographic Reach and Achievements
 - 11.2.4 Company News and Development
 - 11.2.5 Certifications
 - 11.3 Pfizer, Inc.
 - 11.3.1 Financial Analysis
 - 11.3.2 Product Portfolio
 - 11.3.3 Demographic Reach and Achievements
 - 11.3.4 Company News and Development
 - 11.3.5 Certifications
 - 11.4 Teva Pharmaceuticals
 - 11.4.1 Financial Analysis
 - 11.4.2 Product Portfolio
 - 11.4.3 Demographic Reach and Achievements
 - 11.4.4 Company News and Development
 - 11.4.5 Certifications
 - 11.5 Amgen
 - 11.5.1 Financial Analysis
 - 11.5.2 Product Portfolio
 - 11.5.3 Demographic Reach and Achievements
 - 11.5.4 Company News and Development
 - 11.5.5 Certifications
 - 11.6 Sanofi
 - 11.6.1 Financial Analysis
 - 11.6.2 Product Portfolio
 - 11.6.3 Demographic Reach and Achievements
 - 11.6.4 Company News and Development
 - 11.6.5 Certifications
 - 11.7 Mylan N.V.
 - 11.7.1 Financial Analysis
 - 11.7.2 Product Portfolio
 - 11.7.3 Demographic Reach and Achievements
 - 11.7.4 Company News and Development
 - 11.7.5 Certifications
 - 11.8 Ypsomed
 - 11.8.1 Financial Analysis
 - 11.8.2 Product Portfolio
 - 11.8.3 Demographic Reach and Achievements
 - 11.8.4 Company News and Development
 - 11.8.5 Certifications
 - 11.9 SHL Behring AG
 - 11.9.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.9.2 Product Portfolio
- 11.9.3 Demographic Reach and Achievements
- 11.9.4 Company News and Development
- 11.9.5 Certifications
- 11.10 Biogen
 - 11.10.1 Financial Analysis
 - 11.10.2 Product Portfolio
 - 11.10.3 Demographic Reach and Achievements
 - 11.10.4 Company News and Development
 - 11.10.5 Certifications
- 12 United States Autoinjector Market - Distribution Model (Additional Insight)
 - 12.1 Overview
 - 12.2 Potential Distributors
 - 12.3 Key Parameters for Distribution Partner Assessment
- 13 Key Opinion Leaders (KOL) Insights (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

United States Autoinjector Market Report and Forecast 2025-2034

Market Report | 2025-06-20 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2789.00
	Five User License	\$3909.00
	Corporate License	\$5099.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-26"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com